EuroBiotech: More Articles of Note


> The FDA cleared BioLineRx to trial anti-cancer vaccine AGI-134 in solid tumors. The action sets BioLineRx up to expand the trial beyond the U.K. and Israel by opening sites in the U.S. in the first half of next year. Release 

> eTheRNA immunotherapies opened a new research base in Ghent, Belgium. The site will house the biotech’s enlarged research and preclinical teams. Statement 

> Sylentis presented new data from its failed phase 3 dry eye disease trial. The analysis linked siRNA drug tivanisiran to statistically significant improvements in patients with Sjögren's syndrome. Release

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

> BerGenBio completed enrollment into the second stage of a phase 2 lung cancer trial that is testing AXL inhibitor bemcentinib in combination with Merck’s Keytruda. Statement 

> OMass Therapeutics appointed Rosamond Deegan as CEO. Deegan joins OMass from Bicycle Therapeutics, where she served as chief business officer. Release 

Suggested Articles

The deal sets Roche up to compete with Eli Lilly for patients with RET fusion-positive tumors of organs including the lung and thyroid.

Immuno-oncology drugs have transformed cancer treatment for some patients, but not others. Sanofi is partnering with MD Anderson to figure out why.

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.